Cargando…
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance
BACKGROUND: In patients with rheumatoid arthritis (RA), persistent inflammation and increasing disease activity are associated with increased risk of adverse events (AEs). OBJECTIVES: To assess relationships between RA disease activity and AEs of interest in patients treated with tofacitinib or tumo...
Autores principales: | Karpouzas, George A., Szekanecz, Zoltán, Baecklund, Eva, Mikuls, Ted R., Bhatt, Deepak L., Wang, Cunshan, Sawyerr, Gosford A., Chen, Yan, Menon, Sujatha, Connell, Carol A., Ytterberg, Steven R., Mortezavi, Mahta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629315/ https://www.ncbi.nlm.nih.gov/pubmed/37942277 http://dx.doi.org/10.1177/1759720X231201047 |
Ejemplares similares
-
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
por: Charles-Schoeman, Christina, et al.
Publicado: (2023) -
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
por: Dougados, Maxime, et al.
Publicado: (2023) -
Fracture in clinical studies of tofacitinib in rheumatoid arthritis
por: Hansen, Karen E., et al.
Publicado: (2022) -
Use of Tofacitinib in the Context of COVID‐19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases
por: Mortezavi, Mahta, et al.
Publicado: (2021) -
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
por: Balanescu, Andra-Rodica, et al.
Publicado: (2022)